.svg){kind=small}
No items found.
December 10, 2024
Algorithmiq Joins the QuEra Quantum Alliance to Accelerate Healthcare and Life Sciences Breakthroughs on Neutral-Atom Quantum Computers
Magic state distillation on logical qubits
SEOUL, SOUTH KOREA, and BOSTON, USA, Aug 13, 2024 - QuEra Computing, the leader in neutral-atom quantum computing, and Quantum Intelligence Corp. (QIC), a South Korean pioneer in AI-driven drug development, have announced a strategic partnership. This collaboration is set to transform the way drugs are discovered and developed by harnessing QuEra's cutting-edge neutral atom-type quantum computers.
The partnership will utilize the extraordinary computing power of QuEra's quantum computers to boost the performance of QIC's QUEST platform. This integration of quantum computing with artificial intelligence aims to modernize the traditional approaches to drug development, making the process faster, more precise, and more efficient.
Dr. Hwanho Choi, CEO of QIC, commented on the partnership, "At Quantum Intelligence, we are at the forefront of merging quantum and AI technologies to innovate within the biopharmaceutical industry. Our work with QuEra Computing will allow us to accurately detect potential side effects at the early stages of drug development, greatly reducing risks and improving the safety and effectiveness of new treatments."
QIC's QUEST platform uses algorithms that analyze how electronic charges are distributed in molecules to predict how a drug will behave in the body, evaluating its effectiveness and safety. This partnership will leverage QuEra’s specialized knowledge in quantum computing to enhance these predictions, thus significantly accelerating drug development.
QuEra's neutral-atom quantum computers combine system size, coherence, and advanced processing modes. These computers offer a promising path to large-scale, fault-tolerant quantum computing. Since November 2022, QuEra’s first-generation neutral-atom quantum computers have been publicly accessible via a large public cloud service, and they remain the only neutral-atom platform available for public use. QuEra leads the neutral-atom market, offering dynamic qubit manipulation (qubit shuttling) for flexible and efficient quantum computations. Operating at room temperature, QuEra’s computers are built to integrate seamlessly with classical computing infrastructure.
"This partnership marks an important step in applying quantum computing to drug discovery," said Yuval Boger, Chief Commercial Officer of QuEra Computing. "By combining our strengths in quantum technology with QIC's advanced drug development platform, we hope to achieve significant improvements in how quickly and accurately new medicines are developed and brought to market."
About QuEra Computing
QuEra Computing is the leader in commercializing quantum computers using neutral atoms, which is widely recognized as a highly promising quantum modality. Based in Boston and built on pioneering research from nearby Harvard University and MIT, QuEra operates the world’s largest publicly accessible quantum computer, available over a major public cloud and for on-premises delivery. QuEra is developing large-scale, fault-tolerant quantum computers to tackle classically intractable problems, becoming the partner of choice in the quantum field. Simply put, QuEra is the best way to quantum.
About Quantum Intelligence Corp. (QIC)
Established in 2020 by CEO Dr. Hwanho Choi and CTO Dr. Hong-seok Kang, Quantum Intelligence Corp. is a global leader in integrating quantum computing with artificial intelligence to innovate drug discovery. The company’s advanced platforms aim to exceed conventional drug development methods, ensuring highly accurate predictions of drug effects and safety.
QIC is growing globally, supported by strategic collaborations with entities such as Oxford Quantum Circuits (UK), Quandela (France), Classiq (Israel), and a joint venture with 48Hour Discovery (Canada). These partnerships extend QIC’s reach into essential markets worldwide, enhancing its drug discovery and pharmacological research capabilities. Besides healthcare, QIC is exploring the application of quantum computing in finance, transforming activities like algorithmic trading, risk analysis, and asset management.
QIC’s diverse team of professionals in quantum physics, molecular modeling, and AI is driving innovations that streamline the drug development process, positioning the company as a leader in quantum drug discovery. Their strategy to license out innovations underscores QIC’s potential for significant growth in the pharmaceutical field.
SEOUL, SOUTH KOREA, and BOSTON, USA, Aug 13, 2024 - QuEra Computing, the leader in neutral-atom quantum computing, and Quantum Intelligence Corp. (QIC), a South Korean pioneer in AI-driven drug development, have announced a strategic partnership. This collaboration is set to transform the way drugs are discovered and developed by harnessing QuEra's cutting-edge neutral atom-type quantum computers.
The partnership will utilize the extraordinary computing power of QuEra's quantum computers to boost the performance of QIC's QUEST platform. This integration of quantum computing with artificial intelligence aims to modernize the traditional approaches to drug development, making the process faster, more precise, and more efficient.
Dr. Hwanho Choi, CEO of QIC, commented on the partnership, "At Quantum Intelligence, we are at the forefront of merging quantum and AI technologies to innovate within the biopharmaceutical industry. Our work with QuEra Computing will allow us to accurately detect potential side effects at the early stages of drug development, greatly reducing risks and improving the safety and effectiveness of new treatments."
QIC's QUEST platform uses algorithms that analyze how electronic charges are distributed in molecules to predict how a drug will behave in the body, evaluating its effectiveness and safety. This partnership will leverage QuEra’s specialized knowledge in quantum computing to enhance these predictions, thus significantly accelerating drug development.
QuEra's neutral-atom quantum computers combine system size, coherence, and advanced processing modes. These computers offer a promising path to large-scale, fault-tolerant quantum computing. Since November 2022, QuEra’s first-generation neutral-atom quantum computers have been publicly accessible via a large public cloud service, and they remain the only neutral-atom platform available for public use. QuEra leads the neutral-atom market, offering dynamic qubit manipulation (qubit shuttling) for flexible and efficient quantum computations. Operating at room temperature, QuEra’s computers are built to integrate seamlessly with classical computing infrastructure.
"This partnership marks an important step in applying quantum computing to drug discovery," said Yuval Boger, Chief Commercial Officer of QuEra Computing. "By combining our strengths in quantum technology with QIC's advanced drug development platform, we hope to achieve significant improvements in how quickly and accurately new medicines are developed and brought to market."
About QuEra Computing
QuEra Computing is the leader in commercializing quantum computers using neutral atoms, which is widely recognized as a highly promising quantum modality. Based in Boston and built on pioneering research from nearby Harvard University and MIT, QuEra operates the world’s largest publicly accessible quantum computer, available over a major public cloud and for on-premises delivery. QuEra is developing large-scale, fault-tolerant quantum computers to tackle classically intractable problems, becoming the partner of choice in the quantum field. Simply put, QuEra is the best way to quantum.
About Quantum Intelligence Corp. (QIC)
Established in 2020 by CEO Dr. Hwanho Choi and CTO Dr. Hong-seok Kang, Quantum Intelligence Corp. is a global leader in integrating quantum computing with artificial intelligence to innovate drug discovery. The company’s advanced platforms aim to exceed conventional drug development methods, ensuring highly accurate predictions of drug effects and safety.
QIC is growing globally, supported by strategic collaborations with entities such as Oxford Quantum Circuits (UK), Quandela (France), Classiq (Israel), and a joint venture with 48Hour Discovery (Canada). These partnerships extend QIC’s reach into essential markets worldwide, enhancing its drug discovery and pharmacological research capabilities. Besides healthcare, QIC is exploring the application of quantum computing in finance, transforming activities like algorithmic trading, risk analysis, and asset management.
QIC’s diverse team of professionals in quantum physics, molecular modeling, and AI is driving innovations that streamline the drug development process, positioning the company as a leader in quantum drug discovery. Their strategy to license out innovations underscores QIC’s potential for significant growth in the pharmaceutical field.
